榄香烯口服乳联合顺铂、氟尿嘧啶治疗晚期食道癌64例临床评价

Clinical Evaluation on Elemi Oral Emulsion Combined with Cisplatin and Fluorouracil in Treating Advanced Gastric Cancer in 64 Cases

目的评价榄香烯口服乳联合顺铂、氟尿嘧啶治疗晚期食道癌的临床疗效及不良反应。方法将128例晚期食道癌患者随机分为观察组和对照组,各64例。对照组采用顺铂、亚叶酸钙、氟尿嘧啶等进行治疗,观察组在对照组用药基础上加服榄香烯口服乳,21 d为1个周期。治疗2个周期后按RESIST标准评价疗效,并比较两组患者的不良反应及生活质量情况。结果观察组1年生存率为56.25%,明显高于对照组的45.31%(P<0.05);治疗2个周期后,观察组总有效率为39.06%,明显高于对照组的29.69%(P<0.05);两组患者骨髓抑制及消化道不良反应发生率相似;观察组Karnofsky(KPS)评分提高者为32.81%,明显高于对照组的29.69%(P<0.05)。观察组治疗后CEA,CA199,CA724水平明显低于对照组(P<0.05)。结论榄香烯乳联合顺铂、氟尿嘧啶能显著提高晚期食道癌患者的疗效和生活质量,且不增加不良反应,值得临床推广。

Objective To evaluate the clinical efficacy and adverse reactions of Elemi Oral Emulsion combined with cisplatin and fluo-rouracil in treating advanced gastric cancer. Methods 128 patients with advanced gastric cancer were randomLy divided into the obser-vation group and the control group,64 cases in each group. The control group adopted the therapy of cisplatin,calcium folinate and flu-orouracil,etc. On the basis of the control group medication,the observation group was added with Elemi Oral Emulsion,with 21 d as 1 treatment cycle. The curative effect after 2-cycle treatment was evaluated according to the RESIST standard. The adverse reactions and the quality of life were compared between the two groups. Results The 1-year survival rate in the observation group was 56. 25%, which was significantly higher than 45. 31% in the control group（ P 〈 0. 05）;the total effective rate after 2-cycle treatment in the observation group was 39. 06%,which was significantly higher than 29. 69% in the control group（ P 〈 0. 05）;the occurrence rate of myelosuppression and the digestive tract adverse reactions in the two group was similar;the increase rate of KPS in the observation group was 32. 81%,which was significantly higher than 29. 69% in the control group （ P 〈 0. 05 ） . The CEA,CA199 and CA724 levels in the observation group were significantly lower than those in the control group（ P 〈 0. 05）. Conclusion Elemi Oral Emulsion com-bined with cisplatin and fluorouracil can significantly improve the curative efficacy and the quality of life without increasing adverse re-actions in the patients with advanced gastric cancer,which is worthy of clinical promotion.